Pre-earnings options volume in Crispr Therapeutics is 1.1x normal with calls leading puts 9:2. Implied volatility suggests the market is anticipating a move near 5.7%, or $2.99, after results are released. Median move over the past eight quarters is 5.3%.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRSP:
- CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023
- Biotech Alert: Searches spiking for these stocks today
- Cathie Wood’s ARK Investment bought 151.9K shares of Crispr Therapeutics
- Citi sees approval for Crispr Therapeutics, keeps $70 price target
- CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease